Medigene AG reports Q1 2024 financial results, focusing on TCR-T therapies for solid tumors, with a successful capital increase.
Medigene AG, an immuno-oncology firm, reported Q1 2024 financial results, focusing on its TCR-T therapies for solid tumors, such as lead program MDG1015. CEO Selwyn Ho stated their core expertise is generating optimal TCRs, and they're exploring broader applications. A recent capital increase bolsters their financial position, enabling further advancement of therapies and exploration of new parts.
April 26, 2024
3 Articles